RxDoctor Payments DataLook up a doctor →

Alireza Falahati-Nini, MD

Endocrinology, Diabetes & Metabolism · Salt Lake City, UTNPI 1417989971

Payments from drug & device makers

$251,347in general payments, 2019–2025

Across 1,000 payments — averaging $251.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulse Biosciences, Inc.$130K
  • Amgen$55K
  • Radius Health, Inc.$22K
  • Cambridge Interventional LLC$18K
  • Novo Nordisk$6K
  • AstraZeneca$5K
  • plus $16K from 45 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pulse Biosciences, Inc.29$130,225
Amgen(2 entities)99$54,590
Radius Health, Inc.36$22,002
Cambridge Interventional LLC4$18,004
Novo Nordisk125$6,075
AstraZeneca(2 entities)73$4,777
Chiesi USA, Inc.16$3,369
Bayer16$2,101
Boehringer Ingelheim76$1,445
Lilly USA, LLC70$1,145
Abbott93$996
Corcept Therapeutics38$820
Xeris Pharmaceuticals, Inc.42$707
Antares Pharma, Inc.26$610
Medtronic(2 entities)34$529
AbbVie31$496
Merck31$458
Dexcom, Inc.29$380
Recordati_rare_diseases_inc.12$286
Sanofi-aventis U.S. LLC16$260
Amarin Pharma, Inc.14$209
Ascendis Pharma Endocrinology Inc10$190
Novartis9$180
Kyowa Kirin, Inc.2$130
Astellas Pharma US Inc3$127
Insulet Corporation7$115
Tandem Diabetes Care, Inc.6$114
Regeneron Healthcare Solutions, Inc.6$111
Neurocrine Biosciences, Inc.4$110
Johnson & Johnson4$73
BETA Bionics, Inc.3$67
Amphastar Pharmaceuticals, Inc.3$66
Shire North American Group Inc1$60
Boston Scientific3$59
Ascensia Diabetes Care US Inc.3$56
Ultragenyx Pharmaceutical Inc.3$52
Vistapharm, Inc.3$43
Esperion Therapeutics, Inc.2$33
GRT US Holding, Inc.2$33
Lifescan, Inc.2$32
Madrigal Pharmaceuticals2$31
Mannkind Corporation2$27
Amneal Pharmaceuticals LLC2$27
EUSA Pharma (US) LLC1$21
Averitas Pharma Inc.1$20
IBSA Pharma Inc.1$19
Echosens North America, Inc.1$17
Arbor Pharmaceuticals, Inc.1$15
Rhythm Pharmaceuticals, Inc.1$15
Pfizer1$14
Kowa Pharmaceuticals America, Inc.1$12

How this compares

$251,347 in reported general payments places this provider in the 85th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.

See all endocrinology, diabetes & metabolism providers in Utah →

Medicare billing

Part B allowed, 2024
$110,612
Medicare patients
495
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Salt Lake City

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →